Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

Next Previous
Trial Profile

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Zandelisib (Primary) ; Zanubrutinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors MEI Pharma

Most Recent Events

  • 05 May 2023 Status changed from active, no longer recruiting to discontinued.
  • 13 Dec 2022 Results (n=50) assessing the safety and efficacy of zandelisib in combination with zanubrutinib in patients with relapsed/refractory follicular lymphoma (n=31; enrolled between Feb 2020 and Oct 2021) or mantle cell lymphoma (n=19; enrolled between Jan 2021 and May 2022), presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 03 Nov 2022 According to a MEI Pharma media release, results from the study will be presented at the upcoming American Society of Hematology (ASH) 2022 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top